Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives.

doi:10.3390/ijms222010931

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives.

International journal of molecular sciences - 10 Oct 2021

Aleksakhina Svetlana N, Imyanitov Evgeny N

Abstract excerpt

The administration of many cancer drugs is tailored to genetic tests. Some genomic events, e.g., alterations of EGFR or BRAF oncogenes, result in the conformational change of the corresponding proteins and call for the use of mutation-specific compounds. Other genetic perturbations, e.g., HER2 amplifications, ALK translocations or MET exon 14 skipping mutations, cause overproduction of the entire protein or its...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to DNA Repair
Share to ErbB Receptors
Share to Genetic Testing
Share to Mutation
Share to Neoplasms
Share to Proto-Oncogene Proteins B-raf
Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 34681592
DOI: 10.3390/ijms222010931
PMCID: PMC8536080

Provenance

PubMed metadata and Literature Corpus relationships.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics